Healthcare / BiotechnologyNasdaqGS
$6.52
-0.23 (-3.41%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-72.8M · quality 74.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
36/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.0B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-60.8%
↓Gross Margin
N/A
•Debt/Equity
0.03
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
-10.1%
FCF CAGR
—
FCF margin
-3358.3%
FCF / Net income
0.82x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.8M · net income $-115.2M · FCF $-94.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | $2.8M | $2.8M | $4.5M | $5.7M | $5.7M | $4.8M | $4.8M |
| Net Income | $-115.2M | $-115.2M | $-103.1M | $-110.6M | $-104.9M | $-101.0M | $-14.4M |
| EBITDA | $-103.2M | $-103.2M | $-89.1M | $-95.5M | $-91.3M | $-68.6M | $-12.2M |
| EPS | -0.84 | -0.84 | -0.94 | -1.20 | -1.15 | -2.08 | -3.19 |
| Operating Margin | -4479.2% | -4479.2% | -2401.6% | -1647.1% | -1857.5% | -1573.4% | -278.3% |
| Net Margin | -4113.7% | -4113.7% | -2274.1% | -1933.6% | -1825.4% | -2111.3% | -300.3% |
| Balance Sheet | |||||||
| Debt/Equity | 0.03 | 0.03 | 0.06 | 0.09 | 0.08 | 0.01 | — |
| Current Ratio | 6.59 | 6.59 | — | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $-94.0M | $-94.0M | $-72.8M | $-65.5M | $-97.5M | $-98.6M | $-13.2M |
| Returns | |||||||
| ROE | -60.8% | -60.8% | -57.6% | -62.8% | -38.2% | -27.6% | 16.0% |
| Valuation | |||||||
| P/B | 4.71 | 4.71 | 2.01 | 1.89 | 0.80 | — | — |
| Growth & Yield | |||||||
| Revenue Growth | -38.2% | -38.2% | -20.7% | -0.5% | — | 0.0% | — |
| EPS Growth | 10.6% | 10.6% | 21.7% | -4.3% | — | 34.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+146.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.94 → -0.84
Residual
+146.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.